Local News

• Monsanto company declares quarterly dividend  Monsanto Company announced that its Board of Directors has declared a quarterly dividend on its common stock of 24 cents per share. The dividend relates to the company's fourth quarter of its 2008 fiscal year.
  Monsanto Company August 06, 2008  
• Lilly sells its Greenfield, Indiana, operations to Covance  Eli Lilly and Company announced that Covance will buy and operate Lilly's Greenfield Laboratories located in Greenfield, Indiana. In addition, Lilly is finalizing plans to lease a new worldwide headquarters for its animal health division, Elanco, in Hancock County, Indiana.
  Eli Lilly and Company August 06, 2008  
• LabCorp launches chronic kidney disease program  Laboratory Corporation of America(R) announced the launch of a national effort to combat chronic kidney disease in North America. U.S. Senator Elizabeth Dole (R-NC) and representatives of the National Kidney Foundation are joining executives of LabCorp announcing the new initiative.
  LabCorp August 06, 2008  
• Monsanto to pursue divestiture of POSILAC  Monsanto Company announced that it is pursuing a divestiture of its dairy product, POSILAC(R) bovine somatotropin, in the upcoming months. Additional details have not been disclosed at this time.
  Monsanto Company August 06, 2008  
• Genzyme and Isis begin second Phase 3 trial of mipomersen  Genzyme and Isis Pharmaceuticals announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL cholesterol.
  Genzyme Corporation August 06, 2008  
• Lipitor 80 mg reduced the risk of heart attack and stroke in patients  Pfizer announced that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor(R) (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg.
  Pfizer Inc. August 06, 2008  
• Ore Pharmaceuticals acquires rights to develop a second drug candidate from Roche  Ore Pharmaceuticals announced that it has acquired from Roche the exclusive development rights for the clinical-stage compound romazarit. Ore Pharmaceuticals had previously identified potentially novel therapeutic uses for romazarit in metabolic diseases.
  Ore Pharmaceuticals, Inc. August 06, 2008  
• Vanda Pharmaceuticals reports second quarter 2008 results  Vanda Pharmaceuticals announced financial and operational results for the second quarter ended June 30, 2008. Vanda reported research and development (R&D) expenses in the second quarter of 2008 of $5.5 million, compared to first quarter of 2008 R&D expenses of $11.1 million.
  Vanda Pharmaceuticals Inc. August 05, 2008  
• ISENTRESS(R) reduced HIV viral load and increased CD4 cell counts  ISENTRESS(R) (raltegravir), Merck & Co.'s first-in-class integrase inhibitor, in combination with two other anti-HIV medicines, reduced HIV viral load to undetectable levels (less than 50 copies/mL) in 83 percent of previously untreated (treatment-naïve) HIV-infected patients.
  Merck & Co., Inc. August 05, 2008  
• Ninety-six week data on Tibotec investigational NNRTI, TMC278, presented at AIDS 2008  New phase IIb data from Tibotec Pharmaceuticals provides additional information on the safety and efficacy of TMC278, the company's once-daily, investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), as part of HIV combination therapy in treatment-naive adults.
  Johnson & Johnson August 05, 2008  

   (next 10 articles)